1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Gland Pharma Limited
  6. News
  7. Summary
    543245   INE068V01023

GLAND PHARMA LIMITED

(543245)
  Report
End-of-day quote Bombay Stock Exchange  -  05-18
3095.75 INR   -0.30%
05/04Gland Pharma Launches Cancer Treatment Bortezomib for Injection in US; Shares Drop 3%
MT
05/04Gland Pharma Limited Launches Bortezomib for Injection, 3.5 Mg/Vial, Single-Dose Vial in the US Market
CI
04/29GLAND PHARMA : Monitoring Agency Report
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 17-NOV-2021.

11/17/2021 EDT

Certain Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 17-NOV-2021. These Equity Shares will be under lockup for 370 days starting from 12-NOV-2020 to 17-NOV-2021. Details: An aggregate of 20% of the fully diluted post-Issue Equity Share capital of the Company held by the Promoters namely Fosun Singapore and Shanghai Fosun Pharma, shall be locked-in for a period of 3 years from the date of Allotment. The entire pre-issue capital of the company would be locked-in for a period of 1 year from the date of Allotment.


© S&P Capital IQ 2021
All news about GLAND PHARMA LIMITED
05/04Gland Pharma Launches Cancer Treatment Bortezomib for Injection in US; Shares Drop 3%
MT
05/04Gland Pharma Limited Launches Bortezomib for Injection, 3.5 Mg/Vial, Single-Dose Vial i..
CI
04/29GLAND PHARMA : Monitoring Agency Report
PU
03/10Gland Pharma Limited Announces Executive Changes
CI
02/16Gland Pharma Limited Submits an Abbreviated New Drug Application to the U.S. Food and D..
CI
01/25Nomura Adjusts Gland Pharma's Price Target to 3,809 Indian Rupees From 3,799 Indian Rup..
MT
01/21TRANSCRIPT : Gland Pharma Limited, Q3 2022 Earnings Call, Jan 21, 2022
CI
01/21Gland Pharma Seeks Acquisition Opportunities
CI
01/21Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months End..
CI
2021Gland Pharma Gains US FDA's Tentative Approval for Cangrelor for Injection
MT
More news
Analyst Recommendations on GLAND PHARMA LIMITED
More recommendations
Financials
Sales 2022 43 949 M 567 M 567 M
Net income 2022 12 552 M 162 M 162 M
Net cash 2022 17 267 M 223 M 223 M
P/E ratio 2022 40,3x
Yield 2022 0,08%
Capitalization 509 B 6 576 M 6 576 M
EV / Sales 2022 11,2x
EV / Sales 2023 8,85x
Nbr of Employees 3 961
Free-Float 38,0%
Chart GLAND PHARMA LIMITED
Duration : Period :
Gland Pharma Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAND PHARMA LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 095,75 INR
Average target price 3 917,77 INR
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Srinivas Sadu CEO, Managing Director & Director
Ravi Shekhar Mitra Chief Financial Officer
Yiu Kwan Lau Independent Chairman
K. V. G. K. Raju Manager-Quality Control & Development
Surapanini Sridevi Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
GLAND PHARMA LIMITED-19.85%6 575
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.23%282 789
ABBVIE INC.12.05%269 361
ELI LILLY AND COMPANY3.64%265 718
ROCHE HOLDING AG-15.26%264 329